Chardan Capital Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA)

In a report released on August 11, Geulah Livshits from Chardan Capital reiterated a Buy rating on Tenaya Therapeutics (TNYAResearch Report), with a price target of $30.00. The company’s shares closed last Friday at $5.61.

According to TipRanks, Livshits is a 5-star analyst with an average return of 28.5% and a 45.25% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Meiragtx Holdings, and Iovance Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tenaya Therapeutics with a $27.00 average price target, a 381.28% upside from current levels. In a report released on August 11, H.C. Wainwright also maintained a Buy rating on the stock with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

TNYA market cap is currently $231.8M and has a P/E ratio of -2.23.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

Read More on TNYA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More